Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy

Eileen W. Stalman*, Luuk Wieske, Jim B.D. Keijser, the T2B! Immunity against SARS-CoV-2 study group, Koos P.J. van Dam, Laura Y.L. Kummer, Maarten F. Wilbrink, Zoé L.E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Anneke J. van der Kooi, Joost Raaphorst, Mark Löwenberg, R. Bart Takkenberg, Geert R.A.M. D'Haens, Phyllis I. Spuls, Marcel W. BekkenkAnnelie H. Musters, Nicoline F. Post, Angela L. Bosma, Marc L. Hilhorst, Yosta Vegting, Frederique J. Bemelman, Alexandre E. Voskuyl, Bo Broens, Agner Parra Sanchez, Cécile A.C.M. van Els, Jelle de Wit, Abraham Rutgers, Karina de Leeuw, Barbara Horváth, Jan J.G.M. Verschuuren, Annabel M. Ruiter, Lotte van Ouwerkerk, Diane van der Woude, Renée C.F. Allaart, Y. K. Onno Teng, Pieter van Paassen, Matthias H. Busch, Esther Brusse, Pieter A. van Doorn, Adája E. Baars, Dirkjan Hijnen, Corine R.G. Schreurs, W. Ludo van der Pol, H. Stephan Goedee, Olvi Cristianawati, Marcel Jonges

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

10 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy'. Together they form a unique fingerprint.

Immunology and Microbiology